Introduction
Valproic acid (VPA) is an effective anticonvulsant for many types of epilepsy. 1 In vivo, VPA was found to be associated with increased body weight, paralleled by hyperinsulinaemia, and decreased serum levels of the insulin-sensitizing and anti-inflammatory adipocytokine adiponectin in adults and children. [2] [3] [4] In vitro, adiponectin mRNA gene expression was suppressed following VPA treatment in 3T3-L1 adipocytes and C57BL/6J mice. 5 Topiramate (TPM), a sulfamate-substituted monosaccharide, is approved for the treatment of selective seizure disorders. 6 In vivo, weight loss has been noted after TPM treatment 7 and studies in female Zucker diabetic fatty (ZDF) rats demonstrated that TPM treatment leads Seizure (2008) Summary Valproic acid (VPA) is an effective and widely used anticonvulsant, associated with metabolic adverse effects such as weight gain, hyperinsulinemia, hyperleptinemia and hypoadiponectinemia. The aim of this study was to evaluate the influence of VPA and topiramate (TPM) on adiponectin binding receptors, adipoR1 and adipoR2, in human liver cancer cells, HepG2. AdipoR1 but not adipoR2 gene expression was upregulated by VPA treatment. TPM did neither affect adipoR1 nor adipoR2 gene expression. Given the tight association between VPA treatment, metabolic side effects and the adipocytokine-axis, upregulation of adipoR1 possibly represents a favoured and insulin-sensitizing mechanism. # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
to a reduction in blood glucose and triglyceride levels. 8 In vitro, insulin-sensitizing effects of TPM have been observed in liver, skeletal muscle and adipose tissues. 9 In contrast to VPA, adiponectin mRNA concentration and secretion was increased in 3T3-L1 adipocytes stimulated with TPM. 9 Adipose tissue acts as an endocrine organ and releases different factors into the circulation, collectively referred to as adipocytokines (e.g. adiponectin, leptin). 10 Adiponectin has attracted much attention as an adipocytokine with antidiabetic and antiatherogenic properties with reduced concentrations in individuals who are overweight, have cardiovascular diseases or Type 2 diabetes. 11, 12 To date, adiponectin is generally agreed to exert its biological effects by interacting with the adiponectin receptors, adipoR1 and adipoR2, mediating increased AMP-activated protein kinase and peroxisome proliferator-activated receptor alpha ligand activities as well as fatty acid oxidation and glucose uptake. 13 AdipoR1 is mainly expressed in the liver, skeletal muscle and pancreas and binds the globular form of adiponectin with high affinity, whereas adipoR2 is predominantly expressed in the liver exhibiting intermediate affinity to ligands. 14 The direct effect of VPA and TPM on the adiponectin receptor system in an adiponectin-free in vitro model has not been investigated so far. The aim of this study was to evaluate the influence of VPA and TPM on adipoR1 and adipoR2 in human liver cancer cells, HepG2.
Methods

Cell culture
HepG2 cells were obtained from American type Culture Collection (Manassas, VA) and were maintained in culture flasks at 37 8C at 5% CO 2 /95% air in DMEM (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum, 2% antibiotic solution (Gibco, Paisley, Scotland) containing penicillin G sodium/streptomycin sulfate and 1% glutamine. At confluence, all treatments were carried out after serum starvation. Valproic acid sodium salt was obtained from Sigma and dissolved in dimethylsulphoxide (Sigma). Topiramate was a kind gift of Janssen-Cilag AG (Schaffhausen, Swizerland).
HepG2 cells were exposed to VPA for 6 h and 12 h at concentrations of 0.1 mM, 0.5 mM, 1 mM, and 5 mM or to TPM for 12 h, 24 h, and 48 h at concentrations of 4 mM and 40 mM, respectively. In addition, TPM stimulation was performed in a suprapharmacological concentration of 400 mM for 12 h. The incubation conditions and concentrations of VPA or TPM are indicated in the figure legends and performed as published previously. 9, 15, 16 Viability tests showed increased LDH levels in supernatants of cells incubated with VPA for longer than 12 h, indicating toxic effects of VPA on HepG2 cell line after exposure periods longer than 12 h.
Analysis of adipoR1 and adipoR2 mRNA synthesis
Total RNA isolation from HepG2 cells was performed using the GenElute Mammalian Total RNA Kit (Sigma). 1 mg of RNA was reverse-transcribed using the Omniscript RT Kit (Quiagen, Hilden, Germany). Ten percent of each reverse transcription reaction was amplified.
MRNA of adipoR1 and adipoR2 were estimated by quantification of adipoR1, adipoR2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA by the TaqMan real time polymerase chain reaction (PCR) (Perkin Elmer, Vienna, Austria) method expressed as adipoR1/GAPDH cDNA ratio and adipoR2/GAPDH cDNA ratio. Real-time PCR was performed as described in detail previously. 17 
Statistical analysis
SPSS (Version 15.0) was used for statistical analysis. The Mann-Whitney U-test was used to determine significant differences between groups. Statistical significance was accepted at a P-value of less than 0.05. Unless otherwise mentioned, all values are presented as means AE S.E.M.
Results
Upregulation of adipoR1/GAPDH cDNA ratio was found after treatment with 0.1 mM and 0.5 mM VPA, reaching statistical significance at a concentration of 0.1 mM VPA after 6 h exposure period and a 2.5-fold increase at a concentration of 0.5 mM VPA after 12 h exposure period (Fig. 1A) . Furthermore, AdipoR1/GAPDH ratios were significantly increased after treatment with 1 mM and 5 mM VPA after 6 h and 12 h exposure period. Highest concentrations with an almost 2.5-fold and an almost 4-fold increase were observed after 12 h incubation period with 1 mM and 5 mM VPA, respectively (Fig. 1A) .
AdipoR2/GAPDH cDNA ratios tended to increase during VPA stimulation though not reaching statistical significance (Fig. 1B) .
TPM stimulation neither affected the adipoR1/ GAPDH cDNA ratio nor the adipoR2/GAPDH cDNA ratio, respectively, at concentrations and exposure times tested.
Discussion
This is the first study investigating the effect of VPA and TPM on the adiponectin receptor system in human liver cancer cells. The most important finding is that VPA but not TPM increases adipoR1 mRNA expression in an adiponectin-free in vitro model.
The most common adverse effects of VPA treatment are weight gain, hyperinsulinemia, hyperleptinemia and hypoadiponectinemia, limiting its use in clinical practice, especially in children. 3, 4, 18, 19 However, the precise mechanisms underlying VPAassociated metabolic side effects remain unclear. TPM treatment, on the other hand, has been reported to be associated with a decrease in body weight and an improvement of glycaemic homeostasis. 7 Beside its function as energy storage, adipose tissue releases different factors (e.g. adipocytokines) into the circulation. Adipocytokines and their receptor system have recently been suggested as a link between body fat and glucose metabolism. 20, 21 Adiponectin, as an adipocytederived hormone, plays a critical role in the development of type 2 diabetes and insulin resistance (IR). 20, 21 AdipoR1 and adipoR2 serve as receptors for adiponectin and are positively correlated to adiponectin sensitivity. 22 Of note, a number of recent studies, which have focused on the relationship between adipoR1/R2 and insulin sensitivity, indicated that adipoR1, but not adipoR2, is involved in glucose or lipid metabolism. 23, 24 AdipoR1 was found to be correlated with insulin and C-peptide concentrations in vivo, and was found to be a determinant of first-phase insulin secretion independent of body fat. 24 Furthermore, levels of adipoR1 mRNA were increased 2.5-fold in skeletal muscle cells of streptozotocin diabetic mice. 23 In this study, the effect of VPA and TPM on adiponectin receptor mRNA expression in human hepatoma cell line HepG2 was investigated. VPA treatment increases adipoR1 mRNA expression whereas adipoR2 mRNA expression tends to increase without reaching statistical significance (see Fig. 1A and B), excluding compensatory downregulation of adipoR2/GAPDH cDNA ratios for the increased adipoR1/GAPDH cDNA ratios.
Due to the experimental design of this study and the absence of adiponectin production in the liver, we speculate on a direct effect of VPA on the adiponectin receptor system in HepG2 cells. Since adiponectin mRNA expression is known to be downregulated following VPA treatment in vivo 2, 4 and in vitro 5 , increased adipoR1 mRNA expression in liver cells possibly represents a favoured reaction balancing suppressed adiponectin secretion from adipocytes. Hypothetically, upregulation of adipoR1 mRNA expression increases adiponectin-binding capacity leading to an insulin-sensitizing effect and an increased ß-oxidation of free fatty acids mediated through increased adiponectin action. Changes concerning this equilibrium of receptor/ ligand expression in different compartments (e.g. liver, muscle) might contribute to changes in fatty acid oxidation, glucose uptake, obesity-linked IR and the metabolic syndrome in VPA-treated patients. This hypothesis is supported by the differential regulation of serum adiponectin concentrations in overweight and lean VPA-treated children. 4 In contrast to VPA, TPM did neither affect adipoR1 nor adipoR2 mRNA expression. This is similar to current studies, where TPM treatment was found to lead to enhanced muscle, but not liver, insulin sensitivity. 9 Valproic acid and adipoR1 expression 725 The main limitation of this in vitro study is that post-receptor processing as well as the influence of VPA on insulin-signalling or its receptor expression in parallel to adipoR1/R2 mRNA expression are unknown.
In conclusion, this is the first study indicating an upregulation of adiponectin receptor gene expression by VPA, but not by TPM, in vitro. Given the tight association between VPA treatment, metabolic side effects and the adipocytokine-axis, upregulation of adipoR1 may represent a favoured and insulin-sensitizing mechanism. Further in vitro and in vivo studies should investigate the effect of VPA on insulin-signalling, insulin-resistance inducing factors and the adiponectin receptor system in muscle cells.
